Abstract: The present application relates to an immunostimulatory composition including a liposome-nucleic acid complex wherein said complex contains (1) a liposome which, interms of its lipids, includes or consists of a first lipid and a second lipid, wherein the first lipid is a zwitterionic lipid and the second lipid is a cationic lipid, and (2) one or more immunostimulatory oligonucleotides and/or one or more polynucleotides. The application further relates to certain uses of the immunostimulatory composition and to methods for preparing the same. In particular, the application concerns the use of a zwitterionic lipid in an immunostimulatory composition including a liposome-nucleic acid complex to induce type I interferon immune responses and/or to reduce or even bypass TLR-mediated immune responses.

Abstract: The present invention relates to a liquisolid pharmaceutical formulation comprising a porous carrier and an active pharmaceutical ingredient loaded onto a surface of the porous carrier, wherein the active pharmaceutical ingredient is dispersed in propylene carbonate or a mixture of propylene carbonate and a further solvent and the dispersion of the active pharmaceutical ingredient and propylene carbonate or a mixture of propylene carbonate and a further solvent is loaded onto the external surface and the internal surface located inside the pores of the porous carrier thereby forming a liquisolid system, and to a process for manufacturing such a liquisolid pharmaceutical formulation.

Abstract: A composition is for use as a medicament. The composition contains nanoparticles, wherein the nanoparticles contain a polymer selected from the group consisting of PLGA, PLA, PGA, PCL and poly(meth)acrylates, or a lipid. Further, the composition may contain nanoparticles made of a polymer selected from PLGA, amino alkyl methacrylate copolymers, methacrylic acid copolymers, methacrylic ester copolymers, and ammonio alkyl methacrylate copolymers.

Abstract: A composition is for use as a medicament. The composition contains nanoparticles, wherein the nanoparticles contain a polymer selected from the group consisting of PLGA, PLA, PGA, PCL and poly(meth)acrylates, or a lipid. Further, the composition may contain nanoparticles made of a polymer selected from PLGA, amino alkyl methacrylate copolymers, methacrylic acid copolymers, methacrylic ester copolymers, and ammonio alkyl methacrylate copolymers.

Abstract: The present invention relates to core-shell nanoparticles, methods for their production, and their use, in particular as adjuvants. Generally, the nanoparticles of the invention comprise a solid core consisting of a biodegradable polymer and a shell of amphiphilic molecules disposed about said core.

Abstract: Cell culture process includes seeding a suitable culture medium with enterocytes and then, after a delay, seeding the medium containing the enterocytes that have begun to proliferate, with goblet cells.

Abstract: Use of a colloidal carrier for the manufacture of a medicament for inhibiting P-glycoprotein, wherein said colloidal carrier:—encapsulates or adsorbs a pharmacologically active substance, and—comprises P-glycoprotein inhibitor surfactants bound to the colloidal carrier surface.

Abstract: A microencapsulated unsaturated fatty acid or fatty acid compound or mixture of fatty acids and/or fatty acid compounds, and particularly an omega-3-fatty acid or omega-6-fatty acid or an ethyl ester or a glyceride thereof or a mixture of such fatty acids and/or fatty acid compounds. Fatty acid compounds are understood to include derivatives. Particles of the compounds are provided with capsule walls composed of two layers. The inner layer is composed of gelatin A, gelatine B. casein or an alginate, or of a derivative or salt of one of these polymers. The outer layer is composed of gelatin B, gum arabic, pectin or chitosan or a derivative or salt of one of these polymers.